Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Selexid 200mg tablets
0501015P0BBABAB
|
Selexid | Pivmecillinam hydrochloride | Infections | 603 |
|
Rifaximin 200mg tablets
0501070X0AAAAAA
|
Rifaximin | Rifaximin | Infections | 594 |
|
Cefaclor 375mg modified-release tablets
0501021A0AAAGAG
|
Cefaclor | Cefaclor | Infections | 585 |
|
Mepacrine 100mg tablets
0504040M0AAAAAA
|
Mepacrine hydrochloride | Mepacrine hydrochloride | Infections | 562 |
|
Zithromax 200mg/5ml oral suspension
0501050A0BBABAB
|
Zithromax | Azithromycin | Infections | 562 |
|
Phenoxymethylpenicillin 500mg tablets
0501011P0AAAUAU
|
Phenoxymethylpenicillin (Penicillin V) | Phenoxymethylpenicillin (Penicillin V) | Infections | 549 |
|
Ethambutol 400mg tablets
0501090H0AAACAC
|
Ethambutol hydrochloride | Ethambutol hydrochloride | Infections | 532 |
|
Famciclovir 500mg tablets
0503021E0AAADAD
|
Famciclovir | Famciclovir | Infections | 509 |
|
Efracea 40mg modified-release capsules
0501030Z0BBAAAA
|
Efracea | Doxycycline monohydrate | Infections | 480 |
|
Linezolid 600mg tablets
0501070W0AAAAAA
|
Linezolid | Linezolid | Infections | 449 |
|
Tenofovir disoproxil 245mg tablets
0503010H0AAAAAA
|
Tenofovir disoproxil | Tenofovir disoproxil | Infections | 440 |
|
Nirmatrelvir 150mg tablets and Ritonavir 100mg tablets
0503060B0AAAAAA
|
Nirmatrelvir / Ritonavir | Nirmatrelvir with Ritonavir | Infections | 420 |
|
Tamiflu 75mg capsules
0503040B0BBAAAA
|
Tamiflu | Oseltamivir phosphate | Infections | 399 |
|
Vibramycin-D 100mg dispersible tablets
0501030Z0BCAAAB
|
Vibramycin-D | Doxycycline monohydrate | Infections | 394 |
|
Co-amoxiclav 400mg/57mg/5ml oral suspension
0501013K0AAAPAP
|
Co-amoxiclav | Co-amoxiclav (Amoxicillin/clavulanic acid) | Infections | 380 |
|
Targaxan 550mg tablets
0501070X0BEAAAB
|
Targaxan | Rifaximin | Infections | 339 |
|
Terbinafine 250mg/5ml oral suspension
0502050C0AAAFAF
|
Terbinafine hydrochloride (Systemic) | Terbinafine hydrochloride | Infections | 326 |
|
Erythromycin ethyl succinate 500mg/5ml susp sugar free
0501050H0AAANAN
|
Erythromycin ethylsuccinate | Erythromycin ethylsuccinate | Infections | 318 |
|
Fidaxomicin 200mg tablets
0501070ACAAAAAA
|
Fidaxomicin | Fidaxomicin | Infections | 317 |
|
Sodium fusidate 250mg tablets
0501070N0AAADAD
|
Sodium fusidate (Systemic) | Sodium fusidate | Infections | 300 |
|
Vancomycin 250mg capsules
0501070U0AAABAB
|
Vancomycin hydrochloride (Systemic) | Vancomycin hydrochloride | Infections | 298 |
|
Ethambutol 100mg tablets
0501090H0AAABAB
|
Ethambutol hydrochloride | Ethambutol hydrochloride | Infections | 295 |
|
Isoniazid 50mg tablets
0501090K0AAAHAH
|
Isoniazid (Systemic) | Isoniazid | Infections | 292 |
|
Griseofulvin 500mg tablets
0502050B0AAACAC
|
Griseofulvin (Systemic) | Griseofulvin | Infections | 290 |
|
Cefaclor 500mg capsules
0501021A0AAAEAE
|
Cefaclor | Cefaclor | Infections | 287 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.